bullish
Genor Biopharma (6998 HK): First Product Approved in China; Late-Stage Pipeline Entails Visibility
445 Views09 May 2022 00:57
SUMMARY
- JHBP (Genor) (6998 HK) received approval in China for its first commercial drug, GB242, a biosimilar to Remicade (infliximab). Approved indications have an addressable patient population of 10 million.
- The company is also expected to obtain marketing approval for its drug candidate for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) in China this year.
- In-Licensed GB491 (lerociclib) has entered in two phase 3 clinical trials for first and second-line treatments of breast cancer. NDA for GB491 is expected to be filed in 2023.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Genor Biopharma (6998 HK): First Product Approved in China; Late-Stage Pipeline Entails Visibility09 May 2022
- JHBP/Genor (嘉和生物) IPO: Undemanding Valuation with a Strong Investor Line-Up23 Sep 2020
- Genor Biopharma IPO: Strong Clinical Pipeline with Some Potential Blockbusters17 Sep 2020
- Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?25 Jun 2018
x